Avantor, Inc. (NYSE:AVTR) Holdings Reduced by Artemis Investment Management LLP

Artemis Investment Management LLP decreased its position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 3.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,882,087 shares of the company's stock after selling 157,982 shares during the period. Avantor accounts for approximately 1.2% of Artemis Investment Management LLP's portfolio, making the stock its 23rd largest holding. Artemis Investment Management LLP owned approximately 0.57% of Avantor worth $81,796,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its stake in shares of Avantor by 1.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,097,671 shares of the company's stock valued at $23,271,000 after acquiring an additional 18,672 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Avantor by 8.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,434,195 shares of the company's stock worth $94,018,000 after purchasing an additional 350,247 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Avantor by 4.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 25,440 shares of the company's stock worth $539,000 after purchasing an additional 1,119 shares during the period. Seven Eight Capital LP acquired a new position in shares of Avantor in the 2nd quarter valued at $642,000. Finally, First Eagle Investment Management LLC grew its stake in shares of Avantor by 16.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 18,482 shares of the company's stock valued at $392,000 after buying an additional 2,600 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor Stock Performance

NYSE AVTR traded down $0.43 during trading hours on Monday, reaching $22.14. The company's stock had a trading volume of 6,042,606 shares, compared to its average volume of 3,101,021. The stock has a market cap of $15.07 billion, a PE ratio of 48.13, a PEG ratio of 3.42 and a beta of 1.28. The business has a 50-day simple moving average of $21.45 and a 200 day simple moving average of $23.39. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AVTR. Wells Fargo & Company dropped their price target on Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Monday, October 28th. Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. UBS Group reaffirmed a "neutral" rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a research report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Finally, Barclays reduced their target price on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Avantor presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.38.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.